DOJ Takes Aim at CVS for Allegedly Fueling Opioid Crisis with Unlawful Prescriptions

The Department of Justice (DOJ) accused CVS Pharmacy Inc.—the nation’s largest pharmacy chain—of knowingly filling illegal prescriptions for controlled substances. The suit claims CVS violated both the Controlled Substances Act (CSA) and the False Claims Act (FCA), directly contributing to the opioid epidemic that has ravaged communities across the United States.

The timing of this lawsuit, coming on the heels of McKinsey & Company’s $650 million settlement over its own role in the opioid crisis, underscores the DOJ’s intensified crackdown on corporate malfeasance tied to this public health catastrophe.

Filed in Providence, Rhode Island, the DOJ alleges that CVS's pharmacies routinely filled prescriptions for opioids and other controlled substances that were medically unnecessary, fraudulent, or outright dangerous. The lawsuit highlights CVS’s role in dispensing so-called "trinity prescriptions"—a lethal combination of an opioid, a benzodiazepine, and a muscle relaxant—and turning a blind eye to red flags, including high-quantity opioid orders and suspicious prescribers.

According to the DOJ, CVS had every opportunity to intervene. Pharmacists flagged concerns, internal data raised alarms, and external warnings mounted. Yet the company allegedly continued filling questionable prescriptions, allowing dangerous drugs to flow into already vulnerable communities.

Policies That Prioritized Profits

The DOJ didn’t just target CVS’s pharmacies but its corporate structure, which it claims created an environment ripe for abuse. Internal policies like rigid performance metrics, incentive bonuses, and chronic understaffing left pharmacists unable to thoroughly review prescriptions, the complaint states.

Shockingly, the DOJ alleges CVS even restricted pharmacists from sharing information about suspicious prescribers. “CVS chose profits over safety, plain and simple,” said U.S. Attorney Zachary A. Cunha for the District of Rhode Island.

This latest lawsuit follows McKinsey’s $650 million settlement with the DOJ, which marked a significant turning point in holding corporations accountable for their role in the opioid epidemic. McKinsey, a consulting giant, faced criminal and civil penalties for advising Purdue Pharma on aggressive marketing strategies for OxyContin, including targeting “high-value prescribers” notorious for unethical prescribing practices.

Both cases share a chilling narrative: companies knowingly sacrificing public safety for profit. While McKinsey’s role was behind the scenes, shaping strategies that “turbocharged” opioid sales, CVS is accused of directly dispensing addictive substances in violation of federal law.

Principal Deputy Assistant Attorney General Brian Boynton’s remarks on the McKinsey case resonate here: “This settlement sends a clear message: consulting firms—and corporations—prioritizing profits over human lives will be held accountable.”

Real Human Costs

The CVS lawsuit isn’t just about financial penalties; it highlights the devastating human toll. Some patients overdosed and died after filling prescriptions at CVS that should have raised immediate red flags.

“Pharmacies are the last line of defense in preventing dangerous drugs from reaching the wrong hands,” said DEA Administrator Anne Milgram. “CVS failed in that responsibility.”

The McKinsey settlement further underscores the scope of the crisis, with nearly 727,000 lives lost to opioid overdoses since 1999. Together, these cases paint a grim portrait of how corporate decisions can ripple out, fueling an epidemic that shows no signs of abating.

The DOJ’s lawsuit seeks more than just monetary penalties from CVS—it aims to force systemic changes. Potential outcomes include massive fines, civil damages under the FCA, and mandatory reforms to CVS’s compliance practices.

This case also began with a whistleblower complaint filed by Hillary Estright, a former CVS employee, in 2019. Under the FCA’s qui tam provisions, whistleblowers can share in any financial recovery.

Both CVS and McKinsey’s legal troubles highlight the evolving enforcement landscape. Federal authorities are signaling that no player—whether a consulting firm, a pharmacy chain, or a pharmaceutical manufacturer—is immune from scrutiny.

Whether it’s McKinsey’s boardroom strategies or CVS pharmacists overrun by performance quotas, the message is clear that corporate negligence that fuels the opioid crisis will not go unchecked. As the DOJ continues to untangle the web of responsibility, these lawsuits offer a stark reminder of the human cost behind profit-driven decisions.

The GRC Report is your premier destination for the latest in governance, risk, and compliance news. As your reliable source for comprehensive coverage, we ensure you stay informed and ready to navigate the dynamic landscape of GRC. Beyond being a news source, the GRC Report represents a thriving community of professionals who, like you, are dedicated to GRC excellence. Explore our insightful articles and breaking news, and actively participate in the conversation to enhance your GRC journey.